Tessa Romero
Stock Analyst at JP Morgan
(4.40)
# 349
Out of 5,118 analysts
73
Total ratings
50.88%
Success rate
23.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCS Oculis Holding AG | Initiates: Overweight | $38 | $20.00 | +90.00% | 1 | Dec 19, 2025 | |
| AGIO Agios Pharmaceuticals | Maintains: Neutral | $37 → $20 | $27.16 | -26.36% | 7 | Nov 21, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $47 → $15 | $11.54 | +29.98% | 8 | Nov 20, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $57 → $60 | $44.33 | +35.35% | 3 | Nov 18, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $46 → $47 | $45.19 | +4.01% | 6 | Nov 18, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Underweight | $261 → $263 | $3.48 | +7,457.47% | 1 | Nov 18, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $33 → $31 | $27.26 | +13.72% | 11 | Nov 17, 2025 | |
| DYN Dyne Therapeutics | Maintains: Neutral | $18 → $17 | $19.60 | -13.27% | 7 | Nov 14, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $33 → $34 | $24.62 | +38.10% | 11 | Nov 14, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Underweight | n/a | $1.78 | - | 5 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $53 | $61.75 | -14.17% | 5 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $10 | $10.27 | -2.63% | 2 | May 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $28.83 | +31.81% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $14.92 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $29 | $18.20 | +59.34% | 3 | Aug 13, 2024 |
Oculis Holding AG
Dec 19, 2025
Initiates: Overweight
Price Target: $38
Current: $20.00
Upside: +90.00%
Agios Pharmaceuticals
Nov 21, 2025
Maintains: Neutral
Price Target: $37 → $20
Current: $27.16
Upside: -26.36%
Biohaven
Nov 20, 2025
Maintains: Overweight
Price Target: $47 → $15
Current: $11.54
Upside: +29.98%
Xenon Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $57 → $60
Current: $44.33
Upside: +35.35%
Scholar Rock Holding
Nov 18, 2025
Maintains: Overweight
Price Target: $46 → $47
Current: $45.19
Upside: +4.01%
Rocket Pharmaceuticals
Nov 18, 2025
Downgrades: Underweight
Price Target: $261 → $263
Current: $3.48
Upside: +7,457.47%
ACADIA Pharmaceuticals
Nov 17, 2025
Maintains: Overweight
Price Target: $33 → $31
Current: $27.26
Upside: +13.72%
Dyne Therapeutics
Nov 14, 2025
Maintains: Neutral
Price Target: $18 → $17
Current: $19.60
Upside: -13.27%
Edgewise Therapeutics
Nov 14, 2025
Maintains: Overweight
Price Target: $33 → $34
Current: $24.62
Upside: +38.10%
Neumora Therapeutics
Sep 16, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.78
Upside: -
Jun 9, 2025
Maintains: Overweight
Price Target: $71 → $53
Current: $61.75
Upside: -14.17%
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $10.27
Upside: -2.63%
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $28.83
Upside: +31.81%
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $14.92
Upside: -
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $18.20
Upside: +59.34%